TG Therapeutics reported $194.32M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Ardelyx USD 157.56M 18.57M Sep/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Bayer EUR 11.97B 43M Jun/2026
Biogen USD 2.22B 159.9M Sep/2026
Corcept Therapeutics USD 11.91M 1.28M Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
J&J USD 15.38B 233M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Novartis USD 6.1B 116M Sep/2026
Novavax USD 18.5M 8.49M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
TG Therapeutics USD 194.32M 46.35M Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026